Phaseline

Targets › BEST1

BEST1 (Bestrophin-1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Aug 2030.

Ligand-gated anion channel that allows the movement of anions across cell membranes when activated by calcium (Ca2+). Allows the movement of chloride and hydrogencarbonate. (UniProt, O76090)

Open in Phaseline: the race on BEST1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Opus GeneticsOPGx-BEST1
Gene therapy delivering BEST1 gene via subretinal injection
BEST1Phase 1ARBAug 2030

Conditions

ARB (1)

Modalities

other (1)

Companies

Opus Genetics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.